TERT and cancer: Interestingly, when we treated mice with gene therapy vectors carrying a catalytically dead mutant allele of Tert that is unable to catalyze the addition of new telomeric repeats, we found a decreased cancer incidence but only when the vector carrying the catalytically dead Tert mutant was administered prior to oncogene activation.